AMPAC Fine Chemicals, a company with demonstrated capabilities in process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients and registered intermediates for pharmaceutical and biotechnology customers, plans an ongoing facilities expansion both in Rancho Cordova, California and La Porte, Texas.

According to the company, the expansion projects served to increase total capacities by 50% since 2013.

"AFC is witnessing robust customer demand for our core technologies combined with our development & manufacturing expertise to support drug candidate maturation from clinical trials into commercial production," reports Dr. Aslam Malik, CEO of AMPAC Fine Chemicals.

"To meet this demand, we are investing over $40M in 2016 for capacity expansion and infrastructure enhancements. AFC's plant expansion is supported by the financial backing of H.I.G. Capital, a major international investment firm with $19B under management." adds Dr. Malik.

"New facilities add nine reactors (500 – 2000 gal), Heinkel® Hastelloy® (HF-800) centrifuges plus additional solids handing and processing equipment necessary to support on-going production of cGMP intermediates and APIs," shares Joseph Campbell, AFC VP of Operations and Engineering. "These two facilities benefit from AFC's extensive experience in elimination of Foreign Object & Debris (FOD) and containment of potent compounds," adds Mr. Campbell.